GSK plc (LON:GSK) Announces Dividend of GBX 15

GSK plc (LON:GSK) announced a dividend on Wednesday, May 1st, Upcoming.Co.Uk reports. Shareholders of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share on Thursday, July 11th. This represents a yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 16th. The official announcement can be viewed at this link.

GSK Trading Up 0.6 %

LON:GSK opened at GBX 1,716 ($21.56) on Thursday. The stock has a market cap of £70.18 billion, a price-to-earnings ratio of 1,420.83, a PEG ratio of 1.12 and a beta of 0.27. The company has a debt-to-equity ratio of 140.82, a quick ratio of 0.73 and a current ratio of 0.88. GSK has a 1 year low of GBX 1,302.60 ($16.36) and a 1 year high of GBX 1,719.80 ($21.60). The business has a fifty day moving average of GBX 1,660.86 and a 200-day moving average of GBX 1,555.08.

Insider Buying and Selling

In related news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction dated Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). In other GSK news, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,382.19). Also, insider Urs Rohner bought 434 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was purchased at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). Insiders own 1.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GSK. Berenberg Bank increased their target price on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a research report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 ($24.49) price objective on shares of GSK in a report on Wednesday, April 17th. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday. Finally, Barclays reaffirmed an “equal weight” rating and set a GBX 1,725 ($21.67) price target on shares of GSK in a research note on Monday, April 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus price target of GBX 1,630.63 ($20.48).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.